Sophia Genetics

SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership

Retrieved on: 
Thursday, April 4, 2024
Genomics, Health, Organization, Algorithm, Entrepreneurship, Partnership, Sophia Genetics, GENETICS, Strand Life Sciences, Medicine, Cancer, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions.

Key Points: 
  • Headquartered in Bangalore, India, Strand is a life sciences technology company with expertise in bioinformatics, laboratory assays, clinical research and software development.
  • "Strand and SOPHiA GENETICS have a shared vision to improve patient health outcomes through precision medicine," said Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS.
  • With their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand will jointly deepen their value propositions.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership

Retrieved on: 
Thursday, April 4, 2024
Genomics, Health, Organization, Algorithm, Entrepreneurship, Partnership, Sophia Genetics, GENETICS, Strand Life Sciences, Medicine, Cancer, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic partnership with Strand Life Sciences, a pioneer in bioinformatics and diagnostics, to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions.

Key Points: 
  • Headquartered in Bangalore, India, Strand is a life sciences technology company with expertise in bioinformatics, laboratory assays, clinical research and software development.
  • "Strand and SOPHiA GENETICS have a shared vision to improve patient health outcomes through precision medicine," said Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS.
  • With their sophisticated technologies and bioinformatics expertise, SOPHiA GENETICS and Strand will jointly deepen their value propositions.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Laboratorio Barnafi-Krause is Live on SOPHiA DDM™

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, CLL, Leukemia, Incidence, Technical, Patient, NGS, Research, Death, GENETICS, Sophia Genetics, Unit production manager, Chronic lymphocytic leukemia, Bone marrow, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.

Key Points: 
  • BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform.
  • Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.
  • With the SOPHiA DDM™ Platform, Laboratorio Barnafi-Krause will offer tailored NGS-based workflows that enable accurate and sensitive characterization of the complex mutational landscape associated with blood disorders.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada

Retrieved on: 
Wednesday, March 20, 2024
Ovarian cancer, Gene, Mutation, BRCA, Genetic testing, Patient, NGS, Research, DNA, Guideline, AI, University, Cancer, Hope, Quality of life, GENETICS, Oncology, Medicine, Clinical trial, Sophia Genetics, HRD, HRR, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
  • This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.
  • It's exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world," said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
  • The SOPHiA DDM™ Comprehensive Profiling Solution coupled with SOPHiA GENETICS' proprietary deep learning algorithm, GIInger™, will provide USask with a widespread look at potential mutations for each patient.

Microsoft announces collaboration with NVIDIA to accelerate healthcare and life sciences innovation with advanced cloud, AI and accelerated computing capabilities

Retrieved on: 
Monday, March 18, 2024
Cloud, Microsoft, MSFT, Genomics, PIN, Microsoft Azure, Organization, Public, Informatics, Public health, Biotechnology, Radiology, Health, Drug discovery, Intelligence, COVID-19, Patient, Research, Cancer, Sophia Genetics, AI, University, Software, GENETICS, Cloud computing, Drug development, Nuance, Catalog, Multimedia, Data management, NVIDIA, DSM-IV codes, Medical device

REDMOND, Wash., March 18, 2024 /PRNewswire/ -- Microsoft Corp. is expanding its collaboration with NVIDIA to bring the power of generative AI, the cloud and accelerated computing to healthcare and life sciences organizations.

Key Points: 
  • REDMOND, Wash., March 18, 2024 /PRNewswire/ -- Microsoft Corp. is expanding its collaboration with NVIDIA to bring the power of generative AI, the cloud and accelerated computing to healthcare and life sciences organizations.
  • The collaboration will bring together the global scale, security and advanced computing capabilities of Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite of computing platforms, software and services to help healthcare and life sciences organizations accelerate innovation and improve patient care.
  • "The convergence of AI, cloud computing and healthcare is set to transform patient care," said Kimberly Powell, vice president of healthcare, NVIDIA.
  • Microsoft is collaborating with NVIDIA to make a future suite of NVIDIA healthcare microservices available on Azure AI for optimized inference and fine-tuning.

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration

Retrieved on: 
Friday, March 15, 2024
Database, Development, Kidney cancer, Patient, Research, Artificial intelligence, National Cancer Institute, AI, Sophia Genetics, GENETICS, Renal cell carcinoma, Medicine, BCB, RCC, Neoplasm, High Authority, AFU, Nature Portfolio, Medical imaging

BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma (RCC), with the results recently published in npj Precision Oncology. The findings of the study showed the artificial intelligence (AI) model co-constructed by SOPHiA GENETICS and UroCCR provided a strong prediction for post-operative outcomes when compared to usual prognostic scores. This publication follows a prior collaboration that demonstrated the value of multimodal analysis on pre-operative kidney cancer upstaging.

Key Points: 
  • This publication follows a prior collaboration that demonstrated the value of multimodal analysis on pre-operative kidney cancer upstaging.
  • UroCCR is one of the world's largest collaborative kidney cancer networks with 51 multidisciplinary clinical teams across France.
  • In 2021, UroCCR partnered with SOPHiA GENETICS to develop an AI-based model to predict whether kidney cancer will progress from a localized tumor after surgery.
  • For more information on the collaboration between SOPHiA GENETICS and UroCCR, visit SOPHiAGENETICS.com and UroCCR.fr.

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration

Retrieved on: 
Friday, March 15, 2024
Database, Development, Kidney cancer, Patient, Research, Artificial intelligence, National Cancer Institute, AI, Sophia Genetics, GENETICS, Renal cell carcinoma, Medicine, BCB, RCC, Neoplasm, High Authority, AFU, Nature Portfolio, Medical imaging

BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma (RCC), with the results recently published in npj Precision Oncology. The findings of the study showed the artificial intelligence (AI) model co-constructed by SOPHiA GENETICS and UroCCR provided a strong prediction for post-operative outcomes when compared to usual prognostic scores. This publication follows a prior collaboration that demonstrated the value of multimodal analysis on pre-operative kidney cancer upstaging.

Key Points: 
  • This publication follows a prior collaboration that demonstrated the value of multimodal analysis on pre-operative kidney cancer upstaging.
  • UroCCR is one of the world's largest collaborative kidney cancer networks with 51 multidisciplinary clinical teams across France.
  • In 2021, UroCCR partnered with SOPHiA GENETICS to develop an AI-based model to predict whether kidney cancer will progress from a localized tumor after surgery.
  • For more information on the collaboration between SOPHiA GENETICS and UroCCR, visit SOPHiAGENETICS.com and UroCCR.fr.

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, MSK, Forecasting, Constant, Sophia Genetics, Pension, Average cost, Growth, Table, NGS, Book of Wisdom, DASA, Liquid biopsy, COVID-19, Eastern Time Zone, Recombinant DNA, HRD, COVID, Neoplasm, Patient, Public expenditure, Platform, FY, Genomics, Microsoft, Research, GENETICS, Cancer, Central European Time, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the fourth quarter and full year 2023 results, and financial guidance for the full year 2024 on Tuesday, March 5, 2024, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.
  • Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.
  • These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans.

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Retrieved on: 
Wednesday, February 7, 2024
Sophia Genetics, GENETICS, DNA, Biomarker, Patient, Diagnosis, Laboratory, Corporate Affairs, AstraZeneca, HRR, Ovarian cancer, HRD, Cancer, NGS, Death, Health equity, Hospital, Pharmaceutical industry

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

Key Points: 
  • The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country.
  • With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain.
  • Together, SOPHiA GENETICS and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
  • Hence our agreement with SOPHiA GENETICS, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer."

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Retrieved on: 
Wednesday, February 7, 2024
Sophia Genetics, GENETICS, DNA, Biomarker, Patient, Diagnosis, Laboratory, Corporate Affairs, AstraZeneca, HRR, Ovarian cancer, HRD, Cancer, NGS, Death, Health equity, Hospital, Pharmaceutical industry

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

Key Points: 
  • The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country.
  • With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain.
  • Together, SOPHiA GENETICS and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
  • Hence our agreement with SOPHiA GENETICS, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer."